We represented ClearPoint Neuro, Inc. (f/k/a MRI Interventions, Inc.), a global therapy-enabling platform company providing navigation and delivery to the brain, in its $17.5 million strategic investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management, with $10.0 million of notes funded by PTC and $7.5 million of notes funded by Petrichor. With the net proceeds from the sale of the notes to PTC and Petrichor, the ClearPoint Neuro intends to repay in full its existing secured indebtedness, and to fund product commercialization, internal research and development, and general corporate requirements. Additionally, we advised ClearPoint Neuro in the draw of $7.5 million additional proceeds from Petrichor in December 2020. ClearPoint Neuro intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.
ClearPoint Neuro, Inc. (f/k/a/ MRI Interventions, Inc.) Closes $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management and Announces Additional $7.5 Million Strategic Investment in December 2020.
You Also May Be Interested In:
ALS Education’s Charter School Management Business Sold to Satori Capital, Epic Partners Backed Company
Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers